Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.
暂无分享,去创建一个
M. Geschwind | M. Erkkinen | Michael D Geschwind | Michael G Erkkinen | Mee-Ohk Kim | Mee‐Ohk Kim | Michael G. Erkkinen
[1] J. Kornak,et al. Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .
[2] G. Campanella,et al. Suicide risk in Huntington's disease. , 1993, Journal of medical genetics.
[3] A. Takeda,et al. [18F]FDG-PET study in dementia with lewy bodies and alzheimer's disease , 2001, Progress in Neuro-psychopharmacology and Biological Psychiatry.
[4] Jane S. Paulsen,et al. Depression and stages of Huntington's disease. , 2005, The Journal of neuropsychiatry and clinical neurosciences.
[5] Jorge Sepulcre,et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.
[6] Nick C. Fox,et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration , 2011, Brain : a journal of neurology.
[7] E. Tolosa,et al. Premotor signs and symptoms of multiple system atrophy , 2012, The Lancet Neurology.
[8] M. Weiner,et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.
[9] D. Craufurd,et al. Psychiatric disorders in preclinical Huntington’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[10] J. Diehl-Schmid,et al. The epidemiology of frontotemporal dementia , 2013, International review of psychiatry.
[11] D. S. Babu. Multiple-system atrophy. , 2015, The New England journal of medicine.
[12] I Litvan,et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. , 1999, Human molecular genetics.
[13] A. Hofman,et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. , 1991, International journal of epidemiology.
[14] Nick C Fox,et al. Symptom onset in autosomal dominant Alzheimer disease , 2014, Neurology.
[15] H. Paulson,et al. Huntington's Disease (HD): Degeneration of Select Nuclei, Widespread Occurrence of Neuronal Nuclear and Axonal Inclusions in the Brainstem , 2014, Brain pathology.
[16] R. Shiwach. Psychopathology in Huntington's disease patients , 1994, Acta psychiatrica Scandinavica.
[17] N. Kumar,et al. The Sydney Multicenter Study of Parkinson's Disease: The Inevitability of Dementia at 20 years , 2009 .
[18] C. Jack,et al. Dementia with Lewy bodies and Alzheimer disease , 2010, Neurology.
[19] B. L. Miller,et al. The natural history of temporal variant frontotemporal dementia , 2005, Neurology.
[20] Kristine Yaffe,et al. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. , 2005, JAMA.
[21] Marian DiFiglia,et al. Huntington Disease , 1998 .
[22] A. Bava,et al. Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms , 2002, European Neurology.
[23] N. Hattori,et al. CLINICOPATHOLOGIC STUDY OF A SNCA GENE DUPLICATION PATIENT WITH PARKINSON DISEASE AND DEMENTIA , 2008, Neurology.
[24] Frederik Barkhof,et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. , 2015, Brain : a journal of neurology.
[25] P. Ljubenkov,et al. A Clinical Guide to Frontotemporal Dementias. , 2016, Focus.
[26] Nick C Fox,et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.
[27] H. Engler,et al. In vivo amyloid imaging with PET in frontotemporal dementia , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[28] J. Hodges,et al. Behavioural symptoms in progressive supranuclear palsy and frontotemporal dementia , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[29] D W Dickson,et al. Atrophy of superior cerebellar peduncle in progressive supranuclear palsy , 2003, Neurology.
[30] K. Ishii,et al. Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. , 2005, AJNR. American journal of neuroradiology.
[31] B. Dubois,et al. “Applause sign” helps to discriminate PSP from FTD and PD , 2005, Neurology.
[32] K. Leenders,et al. Is FDG‐PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration? , 2003, Movement disorders : official journal of the Movement Disorder Society.
[33] N. Quinn,et al. Multiple system atrophy: A review of 203 pathologically proven cases , 1997, Movement disorders : official journal of the Movement Disorder Society.
[34] M. Weiner,et al. Cognition and anatomy in three variants of primary progressive aphasia , 2004, Annals of neurology.
[35] R Brookmeyer,et al. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.
[36] Mathias Jucker,et al. Neurodegenerative diseases: expanding the prion concept. , 2015, Annual review of neuroscience.
[37] Yong-Hee Han,et al. Progression of subcortical atrophy and iron deposition in multiple system atrophy: a comparison between clinical subtypes , 2015, Journal of Neurology.
[38] Alexander Münchau,et al. Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY , 2011, PLoS currents.
[39] F. Sherriff,et al. Memantine for dementia. , 2005, The Cochrane database of systematic reviews.
[40] N. Herrmann,et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. , 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[41] F. Scaravilli,et al. Pure akinesia as initial presentation of PSP: a clinicopathological study. , 2008, Parkinsonism & related disorders.
[42] B. Miller,et al. Classification of primary progressive aphasia and its variants , 2011, Neurology.
[43] P Sandroni,et al. Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.
[44] K Patterson,et al. Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.
[45] Philip Scheltens,et al. The clinical profile of right temporal lobe atrophy. , 2004, Brain : a journal of neurology.
[46] Sonja W. Scholz,et al. SNCA variants are associated with increased risk for multiple system atrophy , 2009, Annals of neurology.
[47] Grant D. Huang,et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. , 2010, The New England journal of medicine.
[48] Joost Dekker,et al. Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study , 2008, BMJ : British Medical Journal.
[49] R. Staudinger,et al. Teaching NeuroImages: “Penguin” or “hummingbird” sign and midbrain atrophy in progressive supranuclear palsy , 2009, Neurology.
[50] M Schwaiger,et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease , 2009, Neurology.
[51] K Patterson,et al. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. , 2000, Brain : a journal of neurology.
[52] F. Niccolini,et al. Neuroimaging in Huntington's disease. , 2014, World journal of radiology.
[53] Guido F. Schauer,et al. Neuroanatomical correlates of behavioural disorders in dementia. , 2005, Brain : a journal of neurology.
[54] Klaus Seppi,et al. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy , 2009, Movement disorders : official journal of the Movement Disorder Society.
[55] A. King,et al. The question of familial meningiomas and schwannomas: , 2000, Neurology.
[56] D. Aarsland,et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[57] D. Y. Lee,et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.
[58] Dorothy Forbes,et al. Exercise programs for people with dementia. , 2015, The Cochrane database of systematic reviews.
[59] S. Prusiner,et al. Transmission of multiple system atrophy prions to transgenic mice , 2013, Proceedings of the National Academy of Sciences.
[60] C. Jack,et al. MRI correlates of neurofibrillary tangle pathology at autopsy , 2008, Neurology.
[61] Y. Hirayasu,et al. Clinical profiles of dementia with Lewy bodies with and without Alzheimer's disease‐like hypometabolism , 2015, International journal of geriatric psychiatry.
[62] J. Weuve,et al. 2016 Alzheimer's disease facts and figures , 2016 .
[63] J. Trojanowski,et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.
[64] W. Poewe,et al. Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group , 2014, Movement disorders : official journal of the Movement Disorder Society.
[65] R. Petersen,et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.
[66] H. Soininen,et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.
[67] O. Suchowersky,et al. Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology , 2013, Neurology.
[68] M. T. Pellecchia,et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry , 2010, Movement disorders : official journal of the Movement Disorder Society.
[69] I G McKeith,et al. MRI volumetric study of dementia with Lewy bodies , 2000, Neurology.
[70] W. Kamphorst,et al. Frontal presentation in progressive supranuclear palsy , 2007, Neurology.
[71] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[72] D. Dickson. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration , 1999, Journal of Neurology.
[73] J. Hoffman,et al. FDG PET imaging in patients with pathologically verified dementia. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[74] G. Frisoni,et al. Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry , 2002, Journal of neurology, neurosurgery, and psychiatry.
[75] B. Lippitz,et al. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. , 1994, Neurosurgery.
[76] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[77] D. F. Brown,et al. Progressive supranuclear palsy with dementia: cortical pathology. , 1999, Journal of neuropathology and experimental neurology.
[78] K. Rankin,et al. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. , 2011, The Journal of clinical psychiatry.
[79] G. Borasio,et al. Inappropriate sexual behaviour in a case of ALS and FTD: Successful treatment with sertraline , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[80] A. Benabid,et al. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. , 1987, Applied neurophysiology.
[81] J. Obeso,et al. Hardware complications in deep brain stimulation: electrode impedance and loss of clinical benefit. , 2012, Parkinsonism & related disorders.
[82] J. Matsumoto,et al. Clinical features and autonomic testing predict survival in multiple system atrophy. , 2015, Brain : a journal of neurology.
[83] A. Hofman,et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.
[84] M. MacDonald,et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion , 2012, Neurology.
[85] Bastiaan R Bloem,et al. Gender differences in Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[86] I. Litvan,et al. Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy , 2001, Neurology.
[87] I G McKeith,et al. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer’s disease , 2003, Neurology.
[88] A. Drzezga,et al. Cerebral Metabolic Dysfunction in Patients with Dementia with Lewy Bodies and Visual Hallucinations , 2008, Dementia and Geriatric Cognitive Disorders.
[89] E M Wijsman,et al. Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. , 1996, American journal of human genetics.
[90] Jeffrey L. Cummings,et al. Neuropsychiatric aspects of progressive supranuclear palsy , 1996, Neurology.
[91] Alan J. Thomas,et al. Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.
[92] C. Rowe,et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[93] Günther Deuschl,et al. Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.
[94] John Hardy,et al. Parkinson's disease , 2009, The Lancet.
[95] Archana Singh-Manoux,et al. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[96] M. Hallett,et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.
[97] Maria Luisa Gorno-Tempini,et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. , 2006, Archives of neurology.
[98] J. Schneider,et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration , 2007, Acta Neuropathologica.
[99] Keith A. Johnson,et al. Brain amyloid and cognition in Lewy body diseases , 2012, Movement disorders : official journal of the Movement Disorder Society.
[100] Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. , 1997, The Journal of clinical psychiatry.
[101] J. Trojanowski,et al. Mutations in COQ2 in familial and sporadic multiple-system atrophy. , 2013, The New England journal of medicine.
[102] J. Trojanowski,et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. , 2011, Archives of neurology.
[103] J. Trojanowski,et al. Clinicopathological correlations in corticobasal degeneration , 2011, Annals of neurology.
[104] Benjamin F. J. Verhaaren,et al. Is dementia incidence declining? , 2012, Neurology.
[105] K. Blennow,et al. CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.
[106] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[107] C. DeCarli,et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.
[108] M. Hayden,et al. Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk , 2014, Movement disorders : official journal of the Movement Disorder Society.
[109] B L Miller,et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia , 2002, Neurology.
[110] K. Marder,et al. Risk of Parkinson's disease among first-degree relatives , 1996, Neurology.
[111] Hiroaki Kazui,et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. , 2002, Annals of neurology.
[112] K. Blennow,et al. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study , 2015, Alzheimer's & Dementia.
[113] S. Gilman,et al. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy , 1994, Annals of neurology.
[114] J. Brandt,et al. The association of CAG repeat length with clinical progression in Huntington disease , 2006, Neurology.
[115] C. van Broeckhoven,et al. The genetics and neuropathology of frontotemporal lobar degeneration , 2012, Acta Neuropathologica.
[116] C. Cusin,et al. Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy. , 2013, General hospital psychiatry.
[117] Guy B. Williams,et al. Patterns of Frontal Lobe Atrophy in Frontotemporal Dementia: A Volumetric MRI Study , 2006, Dementia and Geriatric Cognitive Disorders.
[118] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[119] J. Jankovic,et al. Parkinson disease subtypes. , 2014, JAMA neurology.
[120] M. Mendez,et al. Accuracy of the clinical evaluation for frontotemporal dementia. , 2007, Archives of neurology.
[121] D. Rubinsztein,et al. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. , 2017, Cold Spring Harbor perspectives in medicine.
[122] Sonja W. Scholz,et al. Genetic players in multiple system atrophy: unfolding the nature of the beast , 2011, Neurobiology of Aging.
[123] M. Prince,et al. Epidemiology of dementias and Alzheimer's disease. , 2012, Archives of medical research.
[124] I. McKeith,et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease , 2005, Neurology.
[125] K P Bhatia,et al. The role of DAT-SPECT in movement disorders , 2008, Journal of Neurology, Neurosurgery & Psychiatry.
[126] Howard J. Rosen,et al. Distinctive Neuropsychological Patterns in Frontotemporal Dementia, Semantic Dementia, And Alzheimer Disease , 2003, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.
[127] R. Petersen,et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia , 1999, Neurology.
[128] C. Lyketsos,et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[129] S Minoshima,et al. Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.
[130] J. Rowe,et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes , 2016, Neurology.
[131] C. D. de Jager,et al. APOE alleles predict the rate of cognitive decline in Alzheimer disease , 2005, Neurology.
[132] M. Dale,et al. Anxiety in Huntington's Disease. , 2015, The Journal of neuropsychiatry and clinical neurosciences.
[133] B. Bloem,et al. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders , 2015, Front. Neurol..
[134] D. Eidelberg,et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[135] James Robert Brašić,et al. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.
[136] H. Kretzschmar,et al. Definite multiple system atrophy in a German family , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[137] C. Jack,et al. Voxel-based morphometry in autopsy proven PSP and CBD , 2008, Neurobiology of Aging.
[138] A. Porcellini,et al. Short-term effects of olanzapine in Huntington disease. , 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.
[139] C. Ross,et al. Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.
[140] A. Spector,et al. Cognitive stimulation to improve cognitive functioning in people with dementia. , 2012, The Cochrane database of systematic reviews.
[141] Karen M Rodrigue,et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.
[142] Vincent A Magnotta,et al. Longitudinal change in regional brain volumes in prodromal Huntington disease , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[143] R. Mayeux,et al. Familial aggregation of dementia with Lewy bodies. , 2011, Archives of neurology.
[144] V. Pankratz,et al. Risk factors for dementia with Lewy bodies , 2013, Neurology.
[145] D. Galimberti,et al. Genetics of Frontotemporal Lobar Degeneration , 2012, Front. Neur..
[146] M. Breteler,et al. Familial aggregation of parkinsonism in progressive supranuclear palsy , 2009, Neurology.
[147] L. Golbe,et al. Prevalence and natural history of progressive supranuclear palsy , 1988, Neurology.
[148] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[149] D. Paviour,et al. Commentary on: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism, by , 2005 .
[150] H. Heinsen,et al. Cortical and striatal neurone number in Huntington's disease , 2004, Acta Neuropathologica.
[151] Lisa Kuramoto,et al. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. , 2004, Archives of neurology.
[152] P. Rochon,et al. Antidepressants for agitation and psychosis in dementia. , 2011, The Cochrane database of systematic reviews.
[153] E. Tolosa,et al. Long lasting pure freezing of gait preceding progressive supranuclear palsy: A clinicopathological study , 2007, Movement disorders : official journal of the Movement Disorder Society.
[154] Mark D'Esposito,et al. Progressive Nonfluent Aphasia: Language, Cognitive, and PET Measures Contrasted with Probable Alzheimer's Disease , 1996, Journal of Cognitive Neuroscience.
[155] M. Tsolaki,et al. Rivastigmine for Alzheimer's disease. , 2000, The Cochrane database of systematic reviews.
[156] K. Blennow,et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.
[157] R. D. de Haan,et al. GPi vs STN deep brain stimulation for Parkinson disease , 2016, Neurology.
[158] D J Brooks,et al. DLB and PDD boundary issues , 2007, Neurology.
[159] I. Mackenzie,et al. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia , 2010, The Lancet Neurology.
[160] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[161] R. Newcombe. A life table for onset of Huntington's chorea , 1981, Annals of human genetics.
[162] David Mann,et al. Frontotemporal lobar degeneration: clinical and pathological relationships , 2007, Acta Neuropathologica.
[163] C. Lomen‐Hoerth,et al. Clinical Phenomenology and Neuroimaging Correlates in ALS-FTD , 2011, Journal of Molecular Neuroscience.
[164] M. Farrer,et al. MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy , 2011, Neurology.
[165] Bruce Fischl,et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.
[166] C. Aguilar,et al. Multivariate classification of patients with Alzheimer’s and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study , 2013, Journal of Neurology.
[167] K. Josephs. Capgras syndrome and its relationship to neurodegenerative disease. , 2007, Archives of neurology.
[168] Anthony E. Lang,et al. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD , 2016, Nature Reviews Neurology.
[169] M. T. Pellecchia,et al. Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG) , 2006, Movement disorders : official journal of the Movement Disorder Society.
[170] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[171] Margaret A. Pericak-Vance,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .
[172] R. Nussbaum. Genetics of Synucleinopathies. , 2018, Cold Spring Harbor perspectives in medicine.
[173] Antonio Daniele,et al. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation , 2012, The Lancet Neurology.
[174] F. Pasquier,et al. Frontotemporal Dementia: A Randomised, Controlled Trial with Trazodone , 2004, Dementia and Geriatric Cognitive Disorders.
[175] G. Chiro,et al. Computed tomography, magnetic resonance imaging and positron emission tomography with [18F] fluorodeoxyglucose in multiple system atrophy and pure autonomic failure , 1991, Clinical Autonomic Research.
[176] William W. Seeley,et al. Anterior insula degeneration in frontotemporal dementia , 2010, Brain Structure and Function.
[177] J. Hodges,et al. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. , 2010, Archives of neurology.
[178] I. Mackenzie. The Neuropathology of FTD Associated With ALS , 2007, Alzheimer disease and associated disorders.
[179] R. Coleman,et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.
[180] Susanne Pirker,et al. Dopamine transporter imaging in autopsy‐confirmed Parkinson's disease and multiple system atrophy , 2012, Movement disorders : official journal of the Movement Disorder Society.
[181] J. O'Brien,et al. Patterns of gray matter atrophy in dementia with Lewy bodies: a voxel-based morphometry study , 2011, International Psychogeriatrics.
[182] M. Hayden,et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.
[183] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[184] B. Miller,et al. Neuropsychological, behavioral, and anatomical evolution in right temporal variant frontotemporal dementia: A longitudinal and post-mortem single case analysis , 2014, Neurocase.
[185] Y Ben-Shlomo,et al. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study , 1999, The Lancet.
[186] J. O'Brien,et al. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies , 2013, Psychological Medicine.
[187] F. Tison,et al. Prevalence of multiple system atrophy , 2000, The Lancet.
[188] M. Riepe,et al. Memantine in Moderate-to-severe Alzheimer's Disease , 2006 .
[189] B. Miller,et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. , 2005, Archives of neurology.
[190] J. Trojanowski,et al. Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.
[191] D. Maraganore,et al. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990 , 1997, Neurology.
[192] J. Hodges,et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. , 2010, Brain : a journal of neurology.
[193] C. Geula,et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. , 2012, Brain : a journal of neurology.
[194] C. Morris,et al. Influence of the amyloid precursor protein locus on dementia in Down syndrome , 2004, Neurology.
[195] S. Seneca,et al. Early onset Huntington disease: a neuronal degeneration syndrome , 2004, European Journal of Pediatrics.
[196] N. Jetté,et al. The incidence and prevalence of Huntington's disease: A systematic review and meta‐analysis , 2012, Movement disorders : official journal of the Movement Disorder Society.
[197] D. Jolley,et al. Cost benefits of a medically supervised day treatment program for patients with Alzheimer's disease and other forms of dementia , 1989 .
[198] J. Jankovic,et al. Variable expression of Parkinson's disease , 1990, Neurology.
[199] B L Miller,et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD , 2005, Neurology.
[200] J. Morris,et al. Familial dementia with Lewy bodies: clinicopathologic analysis of two kindreds. , 2002, Neurology.
[201] Gunhild Waldemar,et al. Evidence-based Evaluation of Magnetic Resonance Imaging as a Diagnostic Tool in Dementia Workup , 2005, Topics in magnetic resonance imaging : TMRI.
[202] I. McKeith,et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[203] Alan Thomas,et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross‐sectional comparative study , 2003, Movement disorders : official journal of the Movement Disorder Society.
[204] R. Roos,et al. Huntington's disease: a clinical review , 2010, Orphanet journal of rare diseases.
[205] Vincenzo Bonifati,et al. The genetics of Parkinson's disease: Progress and therapeutic implications , 2013, Movement disorders : official journal of the Movement Disorder Society.
[206] R. Reilmann,et al. Diagnostic criteria for Huntington's disease based on natural history , 2014, Movement disorders : official journal of the Movement Disorder Society.
[207] R. Coleman,et al. Use of Florbetapir-PET for Imaging-Amyloid Pathology , 2011 .
[208] Y. Abe,et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. , 2002, Brain : a journal of neurology.
[209] I Litvan,et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination , 1998, Journal of neurology, neurosurgery, and psychiatry.
[210] D. Knopman,et al. Estimating the Number of Persons with Frontotemporal Lobar Degeneration in the US Population , 2011, Journal of Molecular Neuroscience.
[211] Serggio C. Lanata,et al. The behavioural variant frontotemporal dementia (bvFTD) syndrome in psychiatry , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[212] V. Sossi,et al. Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease , 2011, Annals of neurology.
[213] M. Albert,et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.
[214] Norbert Schuff,et al. Patterns of cerebral atrophy in primary progressive aphasia. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[215] E. Tolosa,et al. Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force , 2007, Movement disorders : official journal of the Movement Disorder Society.
[216] C. Geula,et al. Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. , 2014, Brain : a journal of neurology.
[217] N. Quinn,et al. Survival of patients with pathologically proven multiple system atrophy , 1997, Neurology.
[218] Johannes C. Klein,et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo , 2010, Neurology.
[219] I Litvan,et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.
[220] Mark Hallett,et al. Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.
[221] Sonja W. Scholz,et al. A genome-wide association study in multiple system atrophy , 2016, Neurology.
[222] C Cadilhac,et al. Cognitive impairment in motor neuron disease with bulbar onset , 2001, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[223] M. Breteler,et al. Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.
[224] J. Quinn,et al. Changes in premorbid brain volume predict Alzheimer’s disease pathology , 2003, Neurology.
[225] C. Brayne,et al. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. , 2005, Age and ageing.
[226] J. Hodges,et al. Survival in frontotemporal dementia , 2003, Neurology.
[227] R. Hamilton,et al. Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry , 2000, Brain pathology.
[228] J. Olin,et al. Galantamine for Alzheimer's disease. , 2004, The Cochrane database of systematic reviews.
[229] J. Hardy,et al. Milestones in PD genetics , 2011, Movement disorders : official journal of the Movement Disorder Society.
[230] R J Harvey,et al. Donepezil for dementia due to Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.
[231] Douglas Galasko,et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study , 2000, International journal of geriatric psychiatry.
[232] Nancy Johnson,et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia , 2008, Annals of neurology.
[233] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.
[234] Kazuhiko Yanai,et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. , 2014, Brain : a journal of neurology.
[235] N. Pouratian,et al. Deep brain stimulation for the treatment of Parkinson's disease: efficacy and safety. , 2012, Degenerative neurological and neuromuscular disease.
[236] G. Wenning. Placebo-Controlled Trial of Amantadine in Multiple-System Atrophy , 2005, Clinical neuropharmacology.
[237] J. Jankovic,et al. Functional decline in Parkinson disease. , 2001, Archives of neurology.
[238] Murray Grossman,et al. Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration , 2013, International review of psychiatry.
[239] A. M. Saunders,et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.
[240] A. Kertesz,et al. The cognitive profile of posterior cortical atrophy , 2006 .
[241] B. Bloem,et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. , 2014, Parkinsonism & related disorders.
[242] J. Haines,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.
[243] Eric E. Smith,et al. The Prevalence and Incidence of Frontotemporal Dementia: a Systematic Review , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[244] P. Kempster,et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. , 2008, Brain : a journal of neurology.
[245] D. Craufurd,et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. , 2012, The Journal of neuropsychiatry and clinical neurosciences.
[246] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[247] Andrew Kertesz,et al. The evolution and pathology of frontotemporal dementia. , 2005, Brain : a journal of neurology.
[248] C. Adler,et al. MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI , 2011, Movement disorders : official journal of the Movement Disorder Society.
[249] H. Markowitsch,et al. Amnesic disorders , 2012, The Lancet.
[250] Clifford R Jack,et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. , 2007, Brain : a journal of neurology.
[251] W. Jagust,et al. Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.
[252] Clifford R. Jack,et al. FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimer’s Type , 2013, PloS one.
[253] R. Brookmeyer,et al. APOE genotype and survival in men and women with Alzheimer’s disease , 2002, Neurology.
[254] B. Dubois,et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. , 1999, American journal of human genetics.
[255] D. Neary,et al. Classification and pathology of primary progressive aphasia , 2013, Neurology.
[256] William T. Hu,et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease , 2011, Annals of neurology.
[257] D. Hernandez,et al. Genome-wide estimate of the heritability of Multiple System Atrophy. , 2016, Parkinsonism & related disorders.
[258] Günther Deuschl,et al. Red flags for multiple system atrophy , 2008, Movement disorders : official journal of the Movement Disorder Society.
[259] J. Holton,et al. The neuropathology, pathophysiology and genetics of multiple system atrophy , 2012, Neuropathology and applied neurobiology.
[260] M. Rodríguez. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma. , 1998, Acta radiologica. Supplementum.
[261] G. Alexander,et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.
[262] R. Olney,et al. The effects of executive and behavioral dysfunction on the course of ALS , 2005, Neurology.
[263] K. Jellinger,et al. Pharmacological therapy in progressive supranuclear palsy. , 1998, Archives of neurology.
[264] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[265] M. Carrillo,et al. Imaging dementia: Evidence for amyloid scanning (IDEAS)—a national study to evaluate the clinical utility of amyloid PET , 2015, Alzheimer's & Dementia.
[266] J. Baron,et al. In Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease , 2001, NeuroImage.
[267] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.
[268] Udo Rüb,et al. Degeneration of the Cerebellum in Huntington's Disease (HD): Possible Relevance for the Clinical Picture and Potential Gateway to Pathological Mechanisms of the Disease Process , 2013, Brain pathology.
[269] G. Wenning,et al. Multiple system atrophy. , 2013, Handbook of clinical neurology.
[270] B. Miller,et al. The logopenic/phonological variant of primary progressive aphasia , 2008, Neurology.
[271] I. McKeith,et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study , 2007, The Lancet Neurology.
[272] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[273] Janice E. Knoefel,et al. Apolipoprotein E element 4 association with dementia in a population-based study , 1996, Neurology.
[274] S. DeKosky,et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.
[275] Jane S. Paulsen. Cognitive Impairment in Huntington Disease: Diagnosis and Treatment , 2011, Current neurology and neuroscience reports.
[276] J. Neuhaus,et al. Comparison of family histories in FTLD subtypes and related tauopathies , 2005, Neurology.
[277] R. Perry,et al. Non-Picks frontotemporal dementia imitating schizophrenia in a 22-year-old man , 2003, Journal of Neurology.
[278] B. Miller,et al. Distinct MRI Atrophy Patterns in Autopsy-Proven Alzheimer's Disease and Frontotemporal Lobar Degeneration , 2008, American journal of Alzheimer's disease and other dementias.
[279] C. Jack,et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.
[280] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[281] M. Diamond,et al. Prion-like mechanisms in neurodegenerative diseases , 2010, Nature Reviews Neuroscience.
[282] Peter L. Lantos,et al. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) , 1989, Journal of the Neurological Sciences.
[283] C. Jack,et al. Symmetric corticobasal degeneration (S-CBD). , 2010, Parkinsonism & related disorders.
[284] Maria Luisa Gorno-Tempini,et al. Structural anatomy of empathy in neurodegenerative disease. , 2006, Brain : a journal of neurology.
[285] G. Rabinovici,et al. Atypical Alzheimer's disease , 2016 .
[286] M. Mesulam,et al. Primary progressive aphasia--a language-based dementia. , 2003, The New England journal of medicine.
[287] Jane S. Paulsen,et al. Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.
[288] L. Tan,et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[289] Maria Luisa Gorno-Tempini,et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. , 2008, Archives of neurology.
[290] Brit Mollenhauer,et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.
[291] Jane S. Paulsen,et al. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study , 2014, The Lancet Neurology.
[292] T. Ferman,et al. Family history of dementia is a risk factor for Lewy body disease , 2006, Neurology.
[293] Jennifer L. Whitwell,et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. , 2006, Brain : a journal of neurology.
[294] B. Boeve,et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. , 2013, JAMA neurology.
[295] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[296] A. Lang,et al. The many faces of corticobasal degeneration. , 2007, Parkinsonism & related disorders.
[297] K. Davis,et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. , 1994, Neuroreport.
[298] D. Geschwind,et al. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[299] Alexandra Durr,et al. How much phenotypic variation can be attributed to parkin genotype? , 2003, Annals of neurology.
[300] R. Brookmeyer,et al. Sources of variability in prevalence rates of Alzheimer's disease. , 1995, International journal of epidemiology.
[301] H. Rickards,et al. Changes in mental state and behaviour in Huntington's disease. , 2016, The lancet. Psychiatry.
[302] C. Pantelis,et al. Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. , 2009, The British journal of psychiatry : the journal of mental science.
[303] The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis , 2015, Neurotherapeutics.
[304] E. Londos,et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial , 2009, The Lancet Neurology.
[305] Rajesh Pahwa,et al. Surgical and hardware complications of subthalamic stimulation , 2004, Neurology.
[306] A. Hofman,et al. The impact of APOE on myocardial infarction, stroke, and dementia , 2004, Neurology.
[307] J R Hodges,et al. Incidence of early-onset dementias in Cambridgeshire, United Kingdom , 2008, Neurology.
[308] Jane S. Paulsen,et al. Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.
[309] R. Kopito,et al. Prion-Like Characteristics of Polyglutamine-Containing Proteins. , 2018, Cold Spring Harbor perspectives in medicine.
[310] Dennis W. Dickson,et al. Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau) , 2011, Journal of Molecular Neuroscience.
[311] E. Tolosa,et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[312] J. Trojanowski,et al. The North American Multiple System Atrophy Study Group , 2005, Journal of Neural Transmission.
[313] A. Young,et al. A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.
[314] R. Mayeux,et al. Epidemiology of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[315] E. Tolosa,et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.
[316] R. Nussbaum,et al. Alzheimer's disease and Parkinson's disease. , 2003, The New England journal of medicine.
[317] P. Barreira,et al. Obsessive-compulsive disorders in Pick's disease. , 1994, The Journal of neuropsychiatry and clinical neurosciences.
[318] S. Prusiner. Biology and genetics of prions causing neurodegeneration. , 2013, Annual review of genetics.
[319] A. Young,et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[320] R. Petersen,et al. Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States , 2011, Alzheimer's & Dementia.
[321] Günther Deuschl,et al. The natural history of multiple system atrophy: a prospective European cohort study , 2013, The Lancet Neurology.
[322] J. Trojanowski,et al. A harmonized classification system for FTLD-TDP pathology , 2011, Acta Neuropathologica.
[323] Martin Knapp,et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. , 2012, The New England journal of medicine.
[324] N. Quinn,et al. Multiple system atrophy--the nature of the beast. , 1989, Journal of neurology, neurosurgery, and psychiatry.
[325] Hiroaki Kazui,et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E ε4 allele , 2002 .
[326] M. Grossman,et al. Primary progressive aphasia: clinicopathological correlations , 2010, Nature Reviews Neurology.
[327] Arthur W Toga,et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.
[328] R. McShane,et al. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review , 2012, BMJ Open.
[329] Jennifer Harris,et al. Pathology in Primary Progressive Aphasia Syndromes , 2014, Current Neurology and Neuroscience Reports.
[330] Roberta F. White,et al. Late onset of Huntington's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.